Experimental Antibodies Delayed Viral Rebound During Closely Monitored Treatment Interruption in a Trial
The RIO trial found that long-acting antibodies delayed viral rebound in selected participants, but the approach remains experimental and does not justify…
อ่านภาษาไทย
Contents
The RIO trial studied two long-acting broadly neutralizing antibodies, 3BNC117-LS and 10-1074-LS, in adults who had started antiretroviral therapy (ART) during early HIV infection. ART was stopped only as a closely monitored analytical treatment interruption under a research protocol. The study does not advise people taking ART to stop treatment on their own.
How Was the Trial Designed?
Sixty-eight participants were randomly assigned under blinded conditions to receive the two antibodies or placebo, with 34 people in each group, before a planned ART interruption. Participants were highly selected: they had started ART during early infection, had viral suppression, and met antibody-sensitivity criteria. The findings therefore cannot be assumed to apply to everyone living with HIV.
Main RIO Results
At 20 weeks after ART interruption, 75% of antibody recipients had not reached the study definition of viral rebound, compared with 11% of placebo recipients. The antibodies clearly delayed rebound in this selected group. Some participants nevertheless experienced rebound, and the intervention did not cure HIV.
Why Should People Not Stop ART Themselves?
- Research interruptions involve frequent viral-load tests, predefined restart criteria, and close clinical monitoring.
- The antibodies remain experimental, and HIV sensitivity to them varies between individuals.
- Viral rebound can harm health and may restore the possibility of sexual transmission if no other prevention is used.
Important: Do not stop or change ART without your HIV care team. If treatment is difficult, ask the clinic about adherence support or a suitable alternative regimen. RIO is an important step toward future ART-free viral control, but this approach is not current standard care.
Verified references
Links and relevance to the article’s main topic were reviewed on 13 August 2026. Each source supports only the scope stated in the original document and does not replace personalised medical, legal, or service advice.
- Lancet HIV/PubMed: RIO trial Accessed 13 August 2026
- RIO trial official site Accessed 13 August 2026
- NIH HIVinfo: HIV Treatment Basics Accessed 13 August 2026
